119 related articles for article (PubMed ID: 19191054)
1. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus.
Shapira MY; Resnick IB; Dray L; Aker M; Stepensky P; Elad S; Gesundeheidt B; Samuel S; Or R
Cytotherapy; 2009; 11(1):61-7. PubMed ID: 19191054
[TBL] [Abstract][Full Text] [Related]
2. Alefacept treatment for refractory chronic extensive GVHD.
Shapira MY; Abdul-Hai A; Resnick IB; Bitan M; Tsirigotis P; Aker M; Gesundheit B; Slavin S; Or R
Bone Marrow Transplant; 2009 Feb; 43(4):339-43. PubMed ID: 18850020
[TBL] [Abstract][Full Text] [Related]
3. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.
Shapira MY; Resnick IB; Bitan M; Ackerstein A; Tsirigotis P; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Or R
Bone Marrow Transplant; 2005 Dec; 36(12):1097-101. PubMed ID: 16247429
[TBL] [Abstract][Full Text] [Related]
4. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
[TBL] [Abstract][Full Text] [Related]
5. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
Toor AA; Stiff PJ; Nickoloff BJ; Rodriguez T; Klein JL; Gordon KB
J Dermatolog Treat; 2007; 18(1):13-8. PubMed ID: 17365261
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
Couriel D; Hosing C; Saliba R; Shpall EJ; Andelini P; Popat U; Donato M; Champlin R
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):37-40. PubMed ID: 16399600
[TBL] [Abstract][Full Text] [Related]
9. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease.
Jung JW; Lee YJ; Yoon SC; Kim TI; Kim EK; Seo KY
Am J Ophthalmol; 2015 Mar; 159(3):519-27.e1. PubMed ID: 25498356
[TBL] [Abstract][Full Text] [Related]
10. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
Couriel DR; Saliba R; Escalón MP; Hsu Y; Ghosh S; Ippoliti C; Hicks K; Donato M; Giralt S; Khouri IF; Hosing C; de Lima MJ; Andersson B; Neumann J; Champlin R
Br J Haematol; 2005 Aug; 130(3):409-17. PubMed ID: 16042691
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
14. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
15. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.
Mollee P; Morton AJ; Irving I; Durrant S
Br J Haematol; 2001 Apr; 113(1):217-23. PubMed ID: 11328304
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide for the treatment of chronic graft-versus-host disease.
Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
